Trial
NCT04346355
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Azienda USL Reggio Emilia - IRCCS
Collaborators
—
Condition
COVID-19 Pneumonia
Intervention
Tocilizumab
Why stopped
Based on interim analysis for futility and given an enrolment rate almost nil
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-06-22